Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease
Status:
Terminated
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain
free walking duration on patients with peripheral arterial disease, a condition caused by
decreased blood flow to the muscles in the legs.
Phase:
Phase 2
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute
Collaborator:
American Heart Association
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan